Molecular mechanisms of fibrinolysis

被引:516
作者
Cesarman-Maus, G [1 ]
Hajjar, KA [1 ]
机构
[1] Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA
关键词
plasminogen; plasminogen activators; plasminogen activator inhibitor-1; annexin; 2; thrombin-activatable fibrinolysis inhibitor;
D O I
10.1111/j.1365-2141.2005.05444.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The molecular mechanisms that finely co-ordinate fibrin formation and fibrinolysis are now well defined. The structure and function of all major fibrinolytic proteins, which include serine proteases, their inhibitors, activators and receptors, have been characterized. Measurements of real time, dynamic molecular interactions during fibrinolysis of whole blood clots can now be carried out in vitro. The development of gene-targeted mice deficient in one or more fibrinolytic protein(s) has demonstrated expected and unexpected roles for these proteins in both intravascular and extravascular settings. In addition, genetic analysis of human deficiency syndromes has revealed specific mutations that result in human disorders that are reflective of either fibrinolytic deficiency or excess. Elucidation of the fine control of fibrinolysis under different physiological and pathological haemostatic states will undoubtedly lead to novel therapeutic interventions. Here, we review the fundamental features of intravascular plasmin generation, and consider the major clinical syndromes resulting from abnormalities in fibrinolysis.
引用
收藏
页码:307 / 321
页数:15
相关论文
共 138 条
[1]   CAVEOLAE - WHERE INCOMING AND OUTGOING MESSENGERS MEET [J].
ANDERSON, RGW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :10909-10913
[2]   Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation [J].
Antovic, JP ;
Blombäck, M .
THROMBOSIS RESEARCH, 2002, 106 (01) :59-62
[3]  
AOKI N, 1978, THROMB HAEMOSTASIS, V39, P22
[4]   ABNORMAL PLASMINOGEN - HEREDITARY MOLECULAR ABNORMALITY FOUND IN A PATIENT WITH RECURRENT THROMBOSIS [J].
AOKI, N ;
MOROI, M ;
SAKATA, Y ;
YOSHIDA, N .
JOURNAL OF CLINICAL INVESTIGATION, 1978, 61 (05) :1186-1195
[5]   PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR [J].
BAJZAR, L ;
MANUEL, R ;
NESHEIM, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14477-14484
[6]  
BEHRENDT N, 1990, J BIOL CHEM, V265, P6453
[7]   THE LDL RECEPTOR RELATED PROTEIN, LRP, IS AN APOLIPOPROTEIN-E-BINDING PROTEIN [J].
BEISIEGEL, U ;
WEBER, W ;
IHRKE, G ;
HERZ, J ;
STANLEY, KK .
NATURE, 1989, 341 (6238) :162-164
[8]   Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) [J].
Bouma, BN ;
Meijers, JCM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (07) :1566-1574
[9]  
Brown MS, 1991, CURR OPIN LIPIDOL, V2, P65
[10]  
BU GJ, 1992, J BIOL CHEM, V267, P15595